Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
about
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapyMultiple Sclerosis in Pediatrics: Current Concepts and Treatment OptionsLymphocyte subtypes in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarateInterdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.An update on multiple sclerosis in children: diagnosis, therapies, and prospects for the future.Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.Regulatory Functions of Natural Killer Cells in Multiple Sclerosis.Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.Precision in neuroimmunology.Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.Inhibition of Acute Graft-versus-Host Disease with Retention of Graft-versus-Tumor Effects by Dimethyl Fumarate.Role of Immunological Memory Cells as a Therapeutic Target in Multiple Sclerosis.Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.Relapse outcomes, safety, and treatment patterns in patients diagnosed with relapsing-remitting multiple sclerosis and initiated on subcutaneous interferon β-1a or dimethyl fumarate: a real-world study.Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod.Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility.Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity.Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
P2860
Q26738969-C1E4D249-E071-40FC-A3CD-B1E7112831CDQ28067298-5919546E-56DF-494C-B10F-B9A0DE1A6445Q33613102-9B0433BD-F05F-45CD-BB98-576E8E3A872EQ37615119-E53D0EFD-351E-4A66-B444-CF4DB5BB6D76Q37720346-9A8C5861-9E23-40DF-8BEA-B8FF11A49F34Q38652593-33F18B75-10B8-4AC9-B132-35F92513D76CQ38798794-D92533FE-1F63-4E35-B493-87EE5DE6CF0CQ38992222-BDBD91CE-729D-4178-9EE0-CAF62B9AB2E2Q39032832-77EF7099-DDF4-43ED-AA2C-110922F5492EQ39100528-1E3BEAC4-23D8-4BE1-831C-23C7CE6E68FEQ42361946-AEF57F1E-FB9A-4062-8EF2-508D56B52E6CQ46409637-023D2338-5F5F-4DDA-95C8-9986FC9D2CEEQ47104079-DCFFD9B5-0919-40D4-B7AA-65F68A4BF96CQ47130362-A9887C03-0B5B-471E-BA96-4CD5AFF98791Q47688274-3AA6CA71-27CC-43D9-A0FF-81842F50348FQ47868767-9C7C9596-3FD9-4C85-B3FE-73290FF79643Q47986992-8F9E8716-0938-4D43-9A57-10C391581D1EQ48357779-121FA66B-1422-4061-ACFC-DE2F9AD68F7CQ49354326-3D37B7B2-B549-42FD-B5FF-C6E7FFAB2D3AQ49596719-0FD7EAD7-56BB-467E-B5F0-EBB5B89DBA63Q49800939-A0354452-7B91-41DF-AE0C-18F8181605A5Q49884884-061E7E0E-F18B-4475-A41E-BAE280C07279Q50141471-CE52EE83-550F-4F00-975E-4D35868CBF49Q50577568-EAAE4E25-5330-4160-9F4A-2BC470CEFF47Q53338098-79955724-48B1-4F32-A8B1-9F61C9BAB84FQ53422663-4EF2ECED-AC94-423D-8873-641B220A3A4BQ54761661-36422997-AD0B-4021-B36C-09B121B10F2AQ55117400-EB68733A-ADC7-42C0-838B-661CD9A53042Q55396042-2D77ECD1-1B71-4510-8608-7378BFD536E1
P2860
Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@ast
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@en
type
label
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@ast
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@en
prefLabel
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@ast
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@en
P2093
P2860
P50
P1476
Dimethyl fumarate treatment al ...... subsets in multiple sclerosis.
@en
P2093
Anita Posevitz-Fejfár
Luisa Klotz
Svenja Klinsing
P2860
P356
10.1212/NXI.0000000000000183
P577
2015-12-10T00:00:00Z